Filing Details
- Accession Number:
- 0000950170-25-042724
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2025-03-20 16:35:16
- Reporting Period:
- 2025-03-17
- Filing Date:
- 2025-03-20
- Accepted Time:
- 2025-03-20 16:35:16
- Original Submission Date:
- 2025-03-19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1841387 | Candel Therapeutics Inc. | CADL | Biological Products, (No Disgnostic Substances) (2836) | 522214851 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1923794 | Seshu Tyagarajan | C/O Candel Therapeutics, Inc. 117 Kendrick St., Suite 450 Needham MA 02494 | Chief Technology Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-03-17 | 20,000 | $1.29 | 116,790 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-03-17 | 31,278 | $8.82 | 85,512 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-03-17 | 20,000 | $0.00 | 20,000 | $1.29 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 70,000 | 2033-04-28 | No | 4 | M | Direct |
Footnotes
- This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/15/2024.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.67 to $9.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein.
- This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date.
Billionaire Hedge Funds
